Graziella Donatelli1, Roberto Ceravolo2, Daniela Frosini3, Michela Tosetti4,5, Ubaldo Bonuccelli6, Mirco Cosottini1. 1. Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. 2. Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy. roberto.ceravolo@unipi.it. 3. Neurology Unit, Department of Medical Specialties, AOUP, Pisa, Italy. 4. Laboratory of Medical Physics and Biotechnologies for Magnetic Resonance, IRCCS, Stella Maris, Pisa, Italy. 5. Imago7 Research Foundation, Pisa, Italy. 6. Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy.
Abstract
PURPOSE OF REVIEW: With a high signal-to-noise ratio, unparalleled spatial resolution, and improved contrasts, ultra-high field MR (≥ 7 T) has great potential in depicting the normal radiological anatomy of smaller structures in the brain and can also provide more information about morphological, quantitative, and metabolic changes associated with a wide range of brain disorders. By focusing attention on specific brain regions believed to be associated with early pathological change, or by more closely inspecting recognized foci of brain pathology, ultra-high field MR can improve the accuracy and sensitivity of neuroimaging. This article reviews recent studies at ultra-high field about Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). RECENT FINDINGS: The research on AD has mainly focused on detecting the thinning of hippocampal layers and the susceptibility effect supposed to be related to beta-amyloid deposition. In patients with PD, atypical parkinsonisms and subjects at risk of developing motor symptoms of Parkinson's disease, the main aim was to detect changes in the substantia nigra, probably related to increased iron deposition. In patients with ALS, both brain and spinal cord were investigated, with the aim of finding changes in the primary motor cortex and corticospinal tract which reflect neurodegeneration and neuroinflammation. Ultra-high field MR was shown to be useful for detecting subtle brain changes in patients with AD, and possible new diagnostic biomarkers in patients with PD and ALS were discovered. The ability of 7 T MR to provide prognostic biomarkers in subjects at risk for developing synucleinopathies is currently under evaluation.
PURPOSE OF REVIEW: With a high signal-to-noise ratio, unparalleled spatial resolution, and improved contrasts, ultra-high field MR (≥ 7 T) has great potential in depicting the normal radiological anatomy of smaller structures in the brain and can also provide more information about morphological, quantitative, and metabolic changes associated with a wide range of brain disorders. By focusing attention on specific brain regions believed to be associated with early pathological change, or by more closely inspecting recognized foci of brain pathology, ultra-high field MR can improve the accuracy and sensitivity of neuroimaging. This article reviews recent studies at ultra-high field about Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). RECENT FINDINGS: The research on AD has mainly focused on detecting the thinning of hippocampal layers and the susceptibility effect supposed to be related to beta-amyloid deposition. In patients with PD, atypical parkinsonisms and subjects at risk of developing motor symptoms of Parkinson's disease, the main aim was to detect changes in the substantia nigra, probably related to increased iron deposition. In patients with ALS, both brain and spinal cord were investigated, with the aim of finding changes in the primary motor cortex and corticospinal tract which reflect neurodegeneration and neuroinflammation. Ultra-high field MR was shown to be useful for detecting subtle brain changes in patients with AD, and possible new diagnostic biomarkers in patients with PD and ALS were discovered. The ability of 7 T MR to provide prognostic biomarkers in subjects at risk for developing synucleinopathies is currently under evaluation.
Entities:
Keywords:
7 T MRI; Alzheimer’s disease; Amyotrophic lateral sclerosis; Parkinson’s disease; Ultra-high field MR
Authors: Laura E M Wisse; Geert Jan Biessels; Sophie M Heringa; Hugo J Kuijf; Dineke H L Koek; Peter R Luijten; Mirjam I Geerlings Journal: Neurobiol Aging Date: 2014-03-03 Impact factor: 4.673
Authors: Jeff H Duyn; Peter van Gelderen; Tie-Qiang Li; Jacco A de Zwart; Alan P Koretsky; Masaki Fukunaga Journal: Proc Natl Acad Sci U S A Date: 2007-06-22 Impact factor: 11.205
Authors: Roberto De Marzi; Klaus Seppi; Birgit Högl; Christoph Müller; Christoph Scherfler; Ambra Stefani; Alex Iranzo; Eduardo Tolosa; Joan Santamarìa; Elke Gizewski; Michael Schocke; Elisabeth Skalla; Christian Kremser; Werner Poewe Journal: Ann Neurol Date: 2016-04-22 Impact factor: 10.422
Authors: J D Rothstein; M Dykes-Hoberg; C A Pardo; L A Bristol; L Jin; R W Kuncl; Y Kanai; M A Hediger; Y Wang; J P Schielke; D F Welty Journal: Neuron Date: 1996-03 Impact factor: 17.173
Authors: B C Bowen; P M Pattany; W G Bradley; J B Murdoch; F Rotta; A A Younis; R C Duncan; R M Quencer Journal: AJNR Am J Neuroradiol Date: 2000-04 Impact factor: 3.825
Authors: Bradley P Thomas; E Brian Welch; Blake D Niederhauser; William O Whetsell; Adam W Anderson; John C Gore; Malcolm J Avison; Jeffrey L Creasy Journal: J Magn Reson Imaging Date: 2008-11 Impact factor: 4.813
Authors: Miguel Mazón; Juan Francisco Vázquez Costa; Amadeo Ten-Esteve; Luis Martí-Bonmatí Journal: Front Neurosci Date: 2018-10-25 Impact factor: 4.677
Authors: Katarzyna Kochalska; Artur Łazorczyk; Anna Pankowska; Katarzyna Dyndor; Paulina Kozioł; Andrzej Stępniewski; Radoslaw Pietura Journal: Pol J Radiol Date: 2019-04-12